Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan


Manage episode 280403509 series 103551
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC management is finally changing. Additionally, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings are presented, with specific implications for SCLC. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum, Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers, Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings.

600 episodes